HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Premature Birth (Birth, Premature)

CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).
Also Known As:
Birth, Premature; Premature Births; Preterm Birth; Birth, Preterm; Births, Premature; Births, Preterm; Preterm Births
Networked: 8811 relevant articles (379 outcomes, 1581 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Birth Weight (Birth Weights)
2. Pre-Eclampsia (Preeclampsia)
3. Premature Obstetric Labor (Premature Labor)
4. Infections
5. Stillbirth

Experts

1. Menon, Ramkumar: 64 articles (03/2022 - 01/2006)
2. Crowther, Caroline A: 61 articles (01/2022 - 11/2003)
3. Berghella, Vincenzo: 59 articles (10/2022 - 11/2002)
4. Romero, Roberto: 57 articles (06/2022 - 01/2002)
5. Iams, Jay D: 50 articles (12/2021 - 03/2002)
6. Goldenberg, Robert L: 48 articles (04/2022 - 03/2002)
7. Caritis, Steve N: 47 articles (01/2022 - 03/2002)
8. Wapner, Ronald J: 42 articles (01/2022 - 11/2002)
9. Rouse, Dwight J: 41 articles (01/2022 - 12/2002)
10. Mercer, Brian M: 38 articles (01/2021 - 03/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Premature Birth:
1. ProgesteroneFDA LinkGeneric
2. Adrenal Cortex Hormones (Corticosteroids)IBA
3. Fibronectins (Fibronectin)IBA
4. Anti-Bacterial Agents (Antibiotics)IBA
5. Tocolytic Agents (Tocolytics)IBA
6. Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
7. hexanoic acid (hexanoate)IBA
8. 17 alpha-Hydroxyprogesterone Caproate (Delalutin)FDA Link
06/19/2007 - "Prophylactic administration of 17-alpha hydroxyprogesterone caproate (17OHPC) has proven to be effective in the prevention of preterm birth in women with singleton pregnancies with a previous preterm delivery. "
10/01/2011 - "Intramuscular 17 α-hydroxyprogesterone caproate (identical in formulation and manufacturing process to Makena™, thus hereafter referred to as Makena™) 250 mg once weekly, initiated at 16-20 weeks' gestation, was effective in reducing the risk of preterm birth in women with a singleton pregnancy at high risk of delivering preterm in a large, well designed, placebo-controlled trial (n = 463 randomized). "
10/01/2023 - "We report that disparate findings and conclusions between similarly designed rigorous studies may reflect differences in a priori risk and population incidence and extreme care should be taken in interpreting the studies and making decisions regarding efficacy of 17-alpha hydroxyprogesterone caproate for the prevention of preterm birth. "
01/01/2021 - "This clinical opinion is a critical appraisal of the 2 randomized trials examining the efficacy of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth and a chronicle of events in the regulatory process of drug approval to help answer this question. "
11/01/2021 - "To perform a systematic review and meta-analysis of all randomized controlled trials (RCTs) that investigated the clinical benefits of 17-alpha hydroxyprogesterone caproate (17OHPC) in the prevention of recurrent preterm birth (PTB) among singleton pregnant women with a previous history of PTB. "
9. Progestins (Progestagens)IBA
10. Folic Acid (Vitamin M)FDA LinkGeneric

Therapies and Procedures

1. Therapeutics
2. Pessaries
3. Cervical Cerclage
4. Prenatal Care (Care, Prenatal)
5. Bed Rest (Bedrest)